Huashan Hospital, Fudan University, Shanghai, Shanghai Municipality, China (Recruiting) - 11 Jun `26D-2570 tablets for nonsegmental vitiligo

D-2570 tablets for nonsegmental vitiligo

Official title: A Phase 2 Multicenter, Randomized, Parallel-group, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of D-2570 in Subjects With Non-Segmental Vitiligo

Status: Recruiting now

Description:

InventisBio Co., Ltd plans to enroll about 160 participants. The study drug is an experimental oral or topical immune-modulating medicine designed to reduce inflammatory signaling. Researchers hope it will slow melanocyte damage and help skin regain color. Possible effects may include headache, stomach upset, skin irritation, and infections; the full safety profile is still being studied. People ages 18 to 65 may qualify. The study is recruiting at one listed site in China.

Start date: June 11, 2026

Completion date: May 01, 2028

Organizer: InventisBio Co., Ltd

Contact: shilin Sha

Tel.: 1 560 182 667 8

Email: shilin.sha@inventisbio.com

Link: https://clinicaltrials.gov/study/NCT07625891

Clinical Trial Alerts

Sign up and be the first to know about updates on this trial.

This request will be sent with the trial reference D-2570 tablets for nonsegmental vitiligo . By submitting you agree to our Privacy Policy.

FAQOther Questions

  • Which diseases most commonly accompany vitiligo?

    Vitiligo is rarely an isolated event. Because it involves an overactive immune system, it often coexists with other autoimmune disorders. According to extensive 10-year clinical...

  • Who is prone to vitiligo?

    Vitiligo can affect anyone, regardless of gender, age, or race. Vitiligo prevalence is between 0.76% and 1.11% of the U.S. population, including around 40% of those with the con...

  • Is there a traditional medicine to treat vitiligo?

    Traditional remedies can be helpful for managing stress or general metabolic health, but when it comes to vitiligo, the evidence is limited. While some natural supplements provi...